Patents Assigned to Centro de Ingenieria Genetica Y Biotecnologia
-
Patent number: 8007776Abstract: Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.Type: GrantFiled: October 8, 2003Date of Patent: August 30, 2011Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Alicia Santos Savio, Ricardo Silva Rodriguez, Yanelis Morera Diaz, Armando Alexei Rodriquez Alfonso, Jose Rafael Martinez Castillo, Haydee Geronimo Perez, Alejandro Moro Soria, Silvio Ernesto Perea Rodriguez
-
Publication number: 20110200628Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: April 26, 2011Publication date: August 18, 2011Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Patent number: 7919463Abstract: The present invention is related to polypeptides derived from tilapia growth hormone.Type: GrantFiled: June 23, 2006Date of Patent: April 5, 2011Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jannel Acosta Alba, Mario Pablo Estrada Garcia, Yamila Carpio Gonzalez, Reynold Morales Fernandez
-
Publication number: 20110064718Abstract: This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the chitinolytic activity-inducing agent and sulfur or a sulfur-producing agent obtaining from microorganisms or chemical compounds are concurrently applied at a range significantly lower than any of the above-mentioned compounds, when they are individually to attain effective control.Type: ApplicationFiled: August 16, 2010Publication date: March 17, 2011Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Jesus Mena Campos, Eulogio Pimentel Vazquez, Armando Tomas Hernadez Garcia, Liuven Veloz Gonzalez, Marieta Marin Bruzos, Oscar Compte Alberto, Marilin Domingo Puente, Licette Leon Barreras, Merardo Pujol Ferrero, Juan Diego Mencho Ponce, Carlos Borroto Nordelo
-
Publication number: 20100316669Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.Type: ApplicationFiled: April 27, 2009Publication date: December 16, 2010Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
-
Patent number: 7799760Abstract: The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine.Type: GrantFiled: August 22, 2008Date of Patent: September 21, 2010Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jorge Berlanga Acosta, Jose I. Fernandez Montequin, Calixto Valdes Perez, Neobalis Franco Perez, Ingrid Rojas Constantin, Hector Santana Milian, Larissa Chacon Corvea, Gerardo E. Guillen Nieto, Luis Herrera Martinez, Leonardo Canan-Haden Frias, Haydee Geronimo Perez, Jorge Sotolongo Pena
-
Patent number: 7790173Abstract: This invention describes a pharmaceutical compound which has the capsid protein of Dengue virus and which is capable of inducing, in the receptor, a protective immune response before the viral challenge, without inducing the Ab-dependent enhancement phenomenon.Type: GrantFiled: September 18, 2006Date of Patent: September 7, 2010Assignee: Centro de Ingenieria Genetica Y BiotecnologiaInventors: Laura Lazo Vázquez, Lisset Hermida Cruz, Carlos López Abarrategui, Beatriz de la Caridad Sierra Vázquez, Susana Vázquez Ramundo, Iris Valdez Prado, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzmán Tirado, Aida Zulueta Morales
-
Patent number: 7736638Abstract: Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15R?) and TNF?-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R? expression is associated to the disease progression.Type: GrantFiled: September 16, 2005Date of Patent: June 15, 2010Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Alicia Santos Savio, Ania Cabrales Rico, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Celia Aurora Arrieta Aguero, Silvio Ernesto Perea Rodriguez
-
Publication number: 20100144642Abstract: Peptides of human heat shock protein of 60 kDa, that constitute epitopes for T cells, as well as their derived peptides, which are modified at the contact sites with the MHC molecule, are useful to induce mechanisms of peripheral tolerance, in particular mechanisms of anergy or mediated by clones of regulatory T cells in patients with Rheumatoid Arthritis. The invention also refers pharmaceutical compositions comprising such peptides for the treatment of Rheumatoid Arthritis.Type: ApplicationFiled: December 30, 2009Publication date: June 10, 2010Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: María del Carmen Domínguez Horta, Gabriel Ramón Padrón Palomares, Nelia López Marín, Norailys Lorenzo Perez, Ariana Barberá Betancourt, Ariadna Hernández Garcia, Vivian Morera Cordova, Carelia Cosme Díaz, Nelson J. Merino García, Ariel Vázquez Bonachea, José Suárez Alba
-
Publication number: 20100047265Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: ApplicationFiled: November 4, 2009Publication date: February 25, 2010Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
-
Publication number: 20090312190Abstract: The present invention is related to the field of the pharmaceutical industry, and describes a conserved area on the surface of the E protein that can be used for the development of wide-spectrum antiviral molecules to be employed in the prophylaxis and/or treatment of infections due to Dengue Virus serotypes 1-4 and other flaviviruses. The invention also covers chimeric proteins to be used as vaccines or as a prophylactic or therapeutic treatment against the four serotypes of Dengue Virus and other flaviviruses.Type: ApplicationFiled: November 21, 2006Publication date: December 17, 2009Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Glay Chinea Santiago, Vivian Huerta Galindo, Alejandro Miguel Martin Dunn, Jorge Victor Gavilondo Cowley, Noralvis Fleitas Salazar, Osmany Guirola Cruz, Jeovanis Gil Valdés, Aída Zulueta Morales, Lisset Hermida Cruz, Marta Ayala Avila, Diamilé Gonzáles Roche, Rolando Paez Meireles, Patricia Gabriela Toledo Mayora, Mónica Sarria Núnez, Alexis Musacchio Lasa, Yuliet Mazola Reyes
-
Publication number: 20090304633Abstract: The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.Type: ApplicationFiled: February 28, 2007Publication date: December 10, 2009Applicants: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA, CENTRO NACIONAL DE SANIDAD AGROPECUARIAInventors: Jorge Roberto Toledo Alonso, Oliberto Sánchez Ramos, Maritza Isidra Barrera Valle, Nancy Elena Figueroa Baile, Yanet Prieto Carratala, Maria Pilar Rodriguez Molto, Maria Teresa Frias Lepoureau, Carlos Guillermo Borroto Nordelo
-
Publication number: 20090274718Abstract: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from Neisseria meningitidis with dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.Type: ApplicationFiled: June 12, 2009Publication date: November 5, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Lisset Hermida Cruz, Rayner Rodriguez Diaz, Laura Lazo Vazquez, Aida Zulueta Morales, Carlos Lopez Abarrategui, Iris Valdes Prado, Ricardo de la C. Silva Rodriguez, Glay Chinea Santiago, Gerardo Enrique Guillen Nieto, Maria Guadalupe Guzman Tirado, Beatriz de la Caridad Sierra Vazquez, Raul Rafael Espinosa Perez
-
Publication number: 20090176703Abstract: The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.Type: ApplicationFiled: November 20, 2006Publication date: July 9, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Juana Maria Lugo Gonzalez, Mario Pablo Estrada Garcia, Alina Rodriguez Mallon, Yamila Carpio Gonzalez, Antonio Morales Rojas, Osmany Rodrigo Gonzalez De Sosa, Reynold Morales Fernandez, Fidel Francisco Herrera Miyares
-
Publication number: 20090136511Abstract: Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor ? subunit (IL15R?) and TNF?-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R? expression is associated to the disease progression.Type: ApplicationFiled: September 16, 2005Publication date: May 28, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Alicia Santos Savio, Ania Cabrales Rico, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Celia Aurora Arrieta Aguero, Silvio Ernesto Perea Rodriguez
-
Publication number: 20090005294Abstract: This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.Type: ApplicationFiled: April 8, 2008Publication date: January 1, 2009Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Silvio Ernesto Perea Rodriquez, Osvaldo Reyes Acosta, Nelson Francisco Santiago Vispo, Yaquelin Puchades Izaguirre, Ricardo Silva Rodriguez, Alejandro Moro Soria, Alicia Santos Savio, Luis Javier Gonzalez Lopez, Belkis Gonzalez Barrios
-
Publication number: 20080312139Abstract: The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-Injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine.Type: ApplicationFiled: August 22, 2008Publication date: December 18, 2008Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Jorge Berlanga Acosta, Jose I. Fernandez Montequin, Calixto Valdes Perez, Neobalis Franco Perez, Ingrid Rojas Constantin, Hector Santana Milian, Larissa Chacon Corvea, Gerardo E. Guillen Nieto, Luis Herrera Martinez, Leonardo Canan-Haden Frias, Haydee Geronimo Perez, Jorge Sotolongo Pena
-
Patent number: 7429384Abstract: A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN ?) receptor. In vitro this protein has a T cell growth stimulating activity, it inhibits the growth stimulating activity of IL-2 in T cells, it inhibits the induction of HLA-DR by IFN ? and it inhibits the antiproliferative activity of ? IFN. This invention can be applied in the field of medicine for the treatment of several pathologies such as autoimmune diseases, graft rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome and atherosclerosis.Type: GrantFiled: May 8, 2003Date of Patent: September 30, 2008Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Iraldo Bello Rivero, Yeny Torres Ruiz, Elizabeth Blanco Garcés, Giselle Pentón Roll, Pedro López Saura
-
Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
Patent number: 7361638Abstract: This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods.Type: GrantFiled: December 17, 2001Date of Patent: April 22, 2008Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Jorge Berlanga Acosta, Gerardo Enrique Guillen Nieto, Diana Garcia Del Barco Herrera, Julio Raul Fernandez Masso, Mario Pablo Estrada Garcia, Isabel Guillen Perez, Jose Suarez Alba, Rebeca Martinez Rodriguez -
Patent number: 7318927Abstract: The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary T cells, which are presented by a wide range of antigens of type Major Histocompatibility Complex (HLA-I). Recombinant poxviruses are obtained from said genes, which are useful for prophylactic and therapeutic vaccination against HIV/AIDS infections, are capable of generating a protective immune cell response in vaccinated laboratory animals and are recognized by the CTL lymphocytes of HIV/AIDS patients.Type: GrantFiled: February 22, 2002Date of Patent: January 15, 2008Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Enrique Iglesias Perez, Dania M. Vazquez Blomquist, Carlos A. Duarte Cano